Passage Bio (NASDAQ:PASG – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($1.47) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.47), FiscalAI reports.
Passage Bio Trading Up 1.6%
Shares of PASG stock traded up $0.06 on Wednesday, hitting $3.84. 4,109 shares of the stock were exchanged, compared to its average volume of 59,383. The firm’s 50 day moving average is $4.14 and its two-hundred day moving average is $6.00. Passage Bio has a one year low of $3.29 and a one year high of $20.00. The firm has a market capitalization of $12.36 million, a PE ratio of -0.34 and a beta of 1.51.
Analyst Upgrades and Downgrades
PASG has been the subject of a number of research reports. Weiss Ratings raised shares of Passage Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Wall Street Zen lowered shares of Passage Bio from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.25.
Get Our Latest Stock Report on PASG
Passage Bio Company Profile
Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies to develop treatments intended to address the underlying genetic causes of severe neurological and neurodegenerative disorders. Its research programs have included PBGM01, an investigational gene therapy for GM1 gangliosidosis, a rare inherited disorder caused by mutations affecting the GLB1 gene.
Featured Articles
- Five stocks we like better than Passage Bio
- On Holding’s Sell-Off Overlooks a Key Part of Its Earnings Story
- Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.
